Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 8/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365881 | 0.87 | CACNA1B (0.61) | CACNA1BCACNA1HKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3366991 | 0.86 | CACNA1B (0.60) | CACNA1BCACNA1HKDM4ESMN1; SMN2PSEN1 | |
| SCHEMBL3365343 | 0.84 | CACNA1B (0.55) | CACNA1BCACNA1HKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL3366887 | 0.81 | CACNA1H (0.49) | CACNA1BCACNA1HPSEN1PSEN2APH1B | |
| SCHEMBL3369004 | 0.79 | CACNA1H (0.47) | CACNA1BCACNA1HPSEN1PSEN2APH1B | |
| SCHEMBL3365014 | 0.78 | LSS (0.53) | CACNA1BCACNA1H | |
| SCHEMBL3365294 | 0.77 | CACNA1B (0.87) | CACNA1BCACNA1HSMN1; SMN2HRH3 | |
| SCHEMBL3368206 | 0.77 | CACNA1H (0.49) | CACNA1BCACNA1HPSEN1PSEN2APH1B | |
| SCHEMBL3365715 | 0.77 | LSS (0.54) | CACNA1BCACNA1HPSEN1PSEN2APH1B | |
| SCHEMBL3367913 | 0.76 | CACNA1H (0.48) | CACNA1BCACNA1HPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| CN-1208329-C | Novel aniline derivative | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| CN-1443179-A | Aniline derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | CACNA1B 2736/4885CACNA1H 1926/4885KDM4E 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.